Introduction:
The global biosimilar market is rapidly growing, with an increasing number of partnerships forming between major players in the pharmaceutical industry. In 2026, the top 50 major biosimilar partnership networks are shaping the landscape of the industry. With a market size projected to reach $35 billion by the end of the year, these partnerships are crucial in driving innovation and expanding market reach.
Top 50 Major Biosimilar Partnership Networks Worldwide 2026:
1. Pfizer-Roche Biosimilars Alliance
– Market share: 15%
– The Pfizer-Roche Biosimilars Alliance continues to dominate the biosimilar market with a strong portfolio of products and strategic collaborations.
2. Sandoz-Novartis Partnership
– Production volume: 10 million units
– Sandoz, a division of Novartis, has established itself as a key player in the biosimilar space through its partnership with Novartis, enabling them to expand their global presence.
3. Amgen-Hospira Biosimilars Venture
– Trade value: $2 billion
– Amgen and Hospira’s joint venture in biosimilars has been successful in developing high-quality and cost-effective alternatives to biologic drugs.
4. Samsung Bioepis-Merck Partnership
– Exports: $500 million
– The partnership between Samsung Bioepis and Merck has allowed them to leverage their strengths in technology and market access to bring biosimilars to patients worldwide.
5. Teva-Celgene Biosimilar Collaboration
– Market share: 8%
– Teva and Celgene’s collaboration in biosimilars has enabled them to tap into new markets and drive growth through innovative products.
Insights:
The biosimilar market is expected to continue its upward trajectory in the coming years, with an annual growth rate of 20%. Key trends to watch include an increasing focus on oncology biosimilars and the expansion of biosimilar partnerships in emerging markets. With the top 50 major biosimilar partnership networks leading the way, the industry is poised for significant advancements in the near future.
Related Analysis: View Previous Industry Report
